Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Flamel Technologies has entered into a new Micropump license agreement for a combination product with a new partner and will begin formulation work immediately. The company has also entered into an additional feasibility agreement involving its Medusa platform with an existing partner and work has commenced.
Subscribe to our email newsletter
Flamel Technologies is engaged in 17 partnered projects and is working with seven of the top-twenty pharmaceutical companies in the world, including a continuing research collaboration with Pfizer.
Stephen Willard, Flamel’s CEO, said: “We are pleased to continue to add new license agreements and projects for both our Micropump and Medusa platforms. We are making significant strides with our existing agreements, but we retain our focus on adding new partnership agreements, particularly with the world’s largest pharmaceutical companies.
In this regard, I am particularly pleased to announce our continuing work with Pfizer, the world’s largest research-based biomedical and pharmaceutical company.”